Recently, a new Ga-68 prostate-specific membrane antigen ligand ([68Ga]Ga-PSMA-11) for PET imaging of metastasized prostate cancer was approved by US Food & Drug Administration (2022), which can detect significantly more prostate lesions than the previously used [18F]fluciclovine (Calais et al. 2019). This evidence concerns the gene FOLH1 and Familial prostate cancer.